InvestorsHub Logo

mick

09/28/20 10:04 AM

#6107 RE: mick #6106

#2 Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
GlobeNewswire
Arbutus Biopharma Corporation
,GlobeNewswire•September 28, 2020

https://finance.yahoo.com/news/arbutus-participate-virtual-fireside-chat-120000168.html

WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 1:00 pm ET.

Arbutus Fireside Chat Presenters:

William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.

A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus’ website at http://www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit http://www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com